SRS Life Sciences Inc Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: SRS Life Sciences Inc Pharmaceutical Import Records from India — 4 Products, $10.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SRS Life Sciences Inc — Pharmaceutical Importer Profile (2026) | 4 Products, $10.9M Trade | TransData Nexus

SRS Life Sciences Inc

Pharmaceutical Importer · Philippines · Cardiovascular Focus · $10.9M Total Trade · DGFT Verified

SRS Life Sciences Inc is a pharmaceutical importer based in Philippines with a total trade value of $10.9M across 4 products in 3 therapeutic categories. Based on 223 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. SRS Life Sciences Inc sources from 2 verified Indian suppliers, with Srs Pharmaceuticals Private Limited accounting for 87.4% of imports.

SRS Life Sciences Inc — Import Portfolio & Supplier Network

SRS Life Sciences Inc import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to SRS Life Sciences Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Srs Pharmaceuticals Private Limited	$4.6M	183	87.4%
S R S Pharmaceuticals Private Limited	$671.2K	28	12.6%

SRS Life Sciences Inc sources from 2 verified Indian suppliers across 138 distinct formulations. The sourcing is — Srs Pharmaceuticals Private Limited accounts for 87.4% of total imports, indicating a strategic single-source relationship.

What Formulations Does SRS Life Sciences Inc Import?

Formulation	Value	Ships
Lustatin 10 (rosuvastatin calcium 10MG)	$412.9K	9
Lustatin 20 (rosuvastatin calcium 20MG)	$200.0K	4
Lustatin 10(rosuvastatin calcium 10MG)alu-alu blister strip x 10s(Box of 30s) tablets reg no. dr-xy43222	$165.0K	4
Vancin (vancomycin hydrochloride for INJ	$150.0K	3
Lustatin 20 (rosuvastatin calcium 20MG)	$150.0K	3
Lustatin 10 (rosuvastatin calcium 10MG )alu-alu blister strip x 10s as per invbatch no.1012240015 1012240016	$150.0K	3
Lustatin 40 (rosuvastatin calcium 40MG)	$141.7K	4
Lustatin 10 (rosuvastatin calcium 10MG) alu-alu blister strip x 10s (Box of 30s) tablets reg no. dr-xy43222	$100.0K	2
Colisan - 2 (colistimethate sodium 2,000,000 lyo powder for INJ. packing: 10 mlvial) (qty. 29310 boxes)	$100.0K	2
Lustatin 10 (rosuvastatin calcium 10MG)alu-alu blister strip x 10s (Box of 30s)tablets reg no.	$100.0K	2
Lustatin 20 (rosuvastatin calcium 20MG)alu-alu blister strip x 10s (Box of 30s)tablets reg no.	$100.0K	2
Lustatin 20 (rosuvastatin calcium 20MG) alu-alu blister strip x 10's(Box of 30's) tablets reg no.	$100.0K	2
Lustatin 20 (rosuvastatin calcium 20MG) alu-alu blister strip x 10s (Box of 30s) tablets reg no. dr-xy43223	$99.1K	2
Lustatin 20(rosuvastatin calcium 20MG)alu-alu blister strip x 10s(Box of 30s) tablets reg no. dr-xy43223	$98.8K	4
Colisan - 2 (colistimethate sodium 2,000,000 lyo powder for INJ. packing: 10	$95.2K	3

SRS Life Sciences Inc imports 138 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Rosuvastatin	Cardiovascular	$4.0M	81	0.9%	16
2	Calcium	Vitamins & Supplements	$3.8M	76	0.4%	14
3	Strip	Medical Devices & Diagnostics	$3.0M	59	1.5%	10
4	Nitroglycerin	Cardiovascular	$118.7K	7	1.2%	15

SRS Life Sciences Inc imports 4 pharmaceutical products across 3 categories into Philippines totaling $10.9M.

SRS Life Sciences Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

SRS Life Sciences Inc. is a pharmaceutical importer and distributor based in the Philippines, specializing in the procurement and distribution of finished pharmaceutical formulations. The company operates as a key player in the Philippine pharmaceutical supply chain, focusing on sourcing and supplying a diverse range of pharmaceutical products to meet the country's healthcare needs. Headquartered in Bonifacio Global City, Taguig City, SRS Life Sciences Inc. plays a pivotal role in ensuring the availability of essential medications across the Philippines.

The company imports a variety of pharmaceutical products, including tablets, capsules, syrups, and injections, primarily from India. This strategic sourcing allows SRS Life Sciences Inc. to offer a comprehensive portfolio of medications across multiple therapeutic categories, thereby contributing significantly to the healthcare sector in the Philippines. By collaborating with reputable manufacturers, the company ensures the delivery of high-quality pharmaceutical products to the Philippine market.

2Distribution Network

SRS Life Sciences Inc. maintains a centralized distribution hub at Unit 810 One Park Drive, 9th Avenue corner 11th Drive, Bonifacio Global City, Taguig City, Philippines. This strategic location facilitates efficient logistics and distribution operations, enabling the company to effectively serve various regions within the Philippines. While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, the centralization of operations suggests a streamlined approach to inventory management and product distribution.

The company's distribution network is designed to ensure timely and reliable delivery of pharmaceutical products to healthcare providers, pharmacies, and hospitals across the country. By leveraging its strategic location and efficient logistics, SRS Life Sciences Inc. plays a crucial role in maintaining the supply chain integrity of the Philippine pharmaceutical market.

3Industry Role

SRS Life Sciences Inc. functions as a pharmaceutical importer and distributor within the Philippine healthcare sector. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company ensures a steady supply of essential medications to meet the diverse healthcare needs of the Philippine population. This role is critical in bridging the gap between global pharmaceutical manufacturers and the local market, facilitating access to a wide range of therapeutic options.

In addition to its importing and distribution activities, SRS Life Sciences Inc. collaborates with various stakeholders in the healthcare industry, including hospitals, clinics, and pharmacies, to ensure the effective delivery of pharmaceutical products. Through these partnerships, the company contributes to the overall efficiency and reliability of the Philippine pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — SRS Life Sciences Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

SRS Life Sciences Inc. demonstrates a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from India. The company's total import value from India amounts to $10.9 million USD, encompassing 223 shipments and 138 unique formulations. This sourcing strategy indicates a reliance on Indian suppliers for a substantial portion of its product portfolio.

The primary suppliers include SRS Pharmaceuticals Private Limited, accounting for $4.6 million USD (87.4% of shipments), and S R S Pharmaceuticals Private Limited, contributing $671,000 USD (12.6% of shipments). This concentration suggests a strategic choice to maintain strong, focused relationships with key suppliers, potentially leading to favorable terms and streamlined logistics.

However, the high supplier concentration also presents risks, such as exposure to supply chain disruptions or regulatory changes in the supplier's country. To mitigate these risks, SRS Life Sciences Inc. may consider diversifying its supplier base and establishing contingency plans to ensure a continuous supply of pharmaceutical products.

2Supply Chain Resilience

SRS Life Sciences Inc.'s supply chain resilience is influenced by its sourcing strategy, which heavily relies on two primary suppliers in India. While this focused approach can lead to operational efficiencies, it also exposes the company to potential risks associated with supply chain disruptions, such as geopolitical issues, natural disasters, or regulatory changes in India.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, registration, and distribution of pharmaceutical products. The FDA is responsible for ensuring that all pharmaceutical products meet the required safety, efficacy, and quality standards before they are made available to the public.

Key legislation governing pharmaceutical imports includes the Food, Drugs, and Devices Act (Republic Act No. 3720), which provides the legal framework for the regulation of health products in the Philippines. Additionally, the FDA Act of 2009 (Republic Act No. 9711) established the FDA as an agency under the Department of Health, granting it the authority to regulate and supervise the safety, efficacy, and quality of health products.

The marketing authorization pathway for Indian generics involves several steps, including the submission of a comprehensive application to the FDA, which must include product dossiers, clinical data, and evidence of Good Manufacturing Practice (GMP) compliance. The FDA evaluates these submissions to ensure that imported generics meet the necessary standards before granting approval for marketing in the Philippines.

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that all pharmaceutical products, including generics, must be registered with the FDA before they can be imported and distributed. The registration process involves submitting detailed product information, including manufacturing details, quality control data, and evidence of safety and efficacy.

SRS Life Sciences Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

SRS Life Sciences Inc.'s product strategy focuses on importing and distributing a diverse range of pharmaceutical formulations across three primary therapeutic categories: cardiovascular, vitamins and supplements, and medical devices and diagnostics. This strategic focus aligns with the company's mission to address pressing healthcare needs in the Philippines by providing essential medications and health solutions.

The company's

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — SRS Life Sciences Inc

What products does SRS Life Sciences Inc import from India?

SRS Life Sciences Inc imports 4 pharmaceutical products across 3 categories. Top imports: Rosuvastatin ($4.0M), Calcium ($3.8M), Strip ($3.0M), Nitroglycerin ($118.7K).

Who supplies pharmaceuticals to SRS Life Sciences Inc from India?

SRS Life Sciences Inc sources from 2 verified Indian suppliers. The primary supplier is Srs Pharmaceuticals Private Limited (87.4% of imports, $4.6M).

What is SRS Life Sciences Inc's total pharmaceutical import value?

SRS Life Sciences Inc's total pharmaceutical import value from India is $10.9M, based on 223 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does SRS Life Sciences Inc focus on?

SRS Life Sciences Inc imports across 3 categories. The largest: Cardiovascular (38.2%), Vitamins & Supplements (34.8%), Medical Devices & Diagnostics (27.0%).

Get Full SRS Life Sciences Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.